Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. The company has one operating segment which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients.
Last trade$2.41
Day change-$0.145 (-5.69%)
Day range$2.40 – $2.69
Volume47,084
Market cap$8M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.65M
Price / earnings
—
Price / book
0.14×
Price / sales
0.02×
EV / sales
0.17×
EV / EBITDA
11.57×
Profitability
Earnings per share
-$5.79
Return on assets
-4.46%
Return on equity
-32.72%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.91×
Current ratio
1.56×
Quick ratio
0.71×
Cash ratio
0.25×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$25.13M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ARAY, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q3 FY2025 Mar 31, 2025
Q2 FY2025 Dec 31, 2024
Revenue
$86.52M
$100.92M
$104.85M
$102.24M
$93.94M
$127.54M
$113.24M
$116.17M
Cost of revenue
$60.44M
$65.84M
$79.55M
$78.17M
$66.93M
$88.56M
$81.62M
$74.28M
Gross profit
$26.08M
$35.08M
$25.29M
$24.07M
$27.01M
$38.98M
$31.63M
$41.89M
Selling, general and administrative
$19M
$21.1M
$19.66M
$18.91M
$24.3M
$23.28M
$19.87M
$23.54M
Research and development
$7.81M
$7.71M
$8.18M
$10.65M
$11.22M
$11.47M
$10.71M
$13.64M
Total operating expenses
$62.59M
$29.55M
$34.38M
$35.64M
$38.32M
$34.75M
$30.58M
$37.19M
Operating income
-$36.5M
$5.52M
-$9.09M
-$11.57M
-$11.31M
$4.23M
$1.05M
$4.71M
Interest expense
-$11.83M
-$8.7M
-$8.45M
-$7.71M
-$8.05M
-$4.23M
-$2.89M
-$2.88M
Income before taxes
$10.65M
-$1.51M
-$11.34M
-$13.2M
-$21.21M
$2.07M
-$840K
$3.23M
Income taxes
$517K
$434K
$468K
$573K
$471K
$948K
$457K
$695K
Net income
$10.13M
-$1.94M
-$11.81M
-$13.77M
-$21.68M
$1.12M
-$1.3M
$2.54M
Net income attributable to common shareholders
$10.13M
-$1.94M
-$11.81M
-$13.77M
-$21.68M
$1.12M
-$1.3M
$2.54M
EBITDA
$1.3M
$8.3M
-$470K
-$3.33M
-$6.83M
$5.83M
$2.62M
$6.22M
Basic earnings per share
$2.80
-$0.61
-$3.60
-$4.40
-$7.20
$0.42
-$0.40
$1.20
Diluted earnings per share
$2.80
-$0.61
-$3.60
-$4.40
-$7.20
$0.43
-$0.40
$0.80
Recent news
Company coverage with links to the original publishers.
Oncology imaging AI market is rapidly evolving, with opportunities expanding tenfold between 2023-2032, driven by advancements in breast and lung screening technologies, with North America leading and Asia-Pacific emerging as a fast-growth region.
The global Robotic Radiotherapy Market is expected to grow from USD 1.15 Billion in 2023 to USD 3.18 Billion by 2032, driven by technological advancements in cancer treatment and increasing precision in radiotherapy systems.
The global radiotherapy market is projected to grow from USD 8.56 billion in 2025 to USD 14.76 billion by 2034, with a 6.25% CAGR. North America leads the market, while Asia Pacific shows the fastest growth. Technological advancements like AI integration, precision targeting, and adaptive therapies are driving market expansion.
The article explores the potential of AI and robotic technologies in surgical medicine, highlighting three companies positioned to lead this medical revolution through advanced robotic surgical systems and AI integration.
Accuray reported Q4 fiscal 2025 results with $128 million revenue, completed debt refinancing, and showed strong international market growth, particularly in emerging markets. The company issued fiscal year 2026 guidance of $471-$485 million in revenue.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.